Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,243 result(s) found for: Cancer cells. Displaying page 1 of 113.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-005498-29 Sponsor Protocol Number: 2.28 Start Date*: 2013-03-21
    Sponsor Name:Celica, Biomedical Center, d.o.o.
    Full Title: Preparation and application of autologous immunohybridoma cells for the treatment of prostate cancer
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-000124-34 Sponsor Protocol Number: PFO-CTC Start Date*: 2013-03-27
    Sponsor Name:PD Dr. Maria De Santis
    Full Title: Circulating Tumor cells in urothelial cancer patients relapsing after or refractory to platinum based first line chemotherapy
    Medical condition: Circulating tumor cells in urothelial cancer patients relapsing after or refractory to platinum based first line chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003662-21 Sponsor Protocol Number: ALKS4230-003 Start Date*: 2023-04-13
    Sponsor Name:Alkermes, Inc.
    Full Title: Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumo...
    Medical condition: Patients with advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007116 Cancer of skin (excl melanoma) LLT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086582 Microsatellite instability-high metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000054-63 Sponsor Protocol Number: HNJ-NKAES-2012 Start Date*: 2012-07-25
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS
    Full Title: Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Medical condition: Relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004043-36 Sponsor Protocol Number: 004:TCELL Start Date*: 2017-04-28
    Sponsor Name:Uppsala University
    Full Title: CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001237-37 Sponsor Protocol Number: NL81058.041.22 Start Date*: 2022-09-22
    Sponsor Name:University Medical Center Utrecht
    Full Title: SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high-intermediate risk endometrial cancer: a pilot study
    Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with high/high-intermediate risk endometrial cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014739 Endometrial cancer stage II PT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005400-40 Sponsor Protocol Number: CT/07.15 Start Date*: 2008-06-03
    Sponsor Name:Vassilis Georgoulias, Prof. of Internal Medicine-Oncology of Medical Dpt University of Crete
    Full Title: A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating cytokeratin-positive tumor cells circulating in the blood of women with brest cancer
    Medical condition: Metastatic breast cancer patients with detectable circulating tumor cells in peripheral blood (>=5 cells/7.5 ml) even after administration of at least one chemotherapy regimen
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010290-21 Sponsor Protocol Number: UMCNONCO200902 Start Date*: 2009-05-20
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer
    Medical condition: advanced or therapy refractory breast cancer, endometrial cancer, or ovarian cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002087-24 Sponsor Protocol Number: CT/11.02 Start Date*: 2011-07-13
    Sponsor Name:Hellenic Oncology Research Group (HORG)
    Full Title: A phase II study of Temsirolimus in patients with advanced hormone - and chemotherapy - resistant prostate cancer.
    Medical condition: Advanced hormone - and chemotherapy - resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000764-42 Sponsor Protocol Number: UC-0140/1606 Start Date*: 2016-10-12
    Sponsor Name:UNICANCER
    Full Title: A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration Afte...
    Medical condition: Patients with ER+ and HER2- primary non-metastatic breast cancer who are eligible to neoadjuvant endocrine therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023457-11 Sponsor Protocol Number: S52798 Start Date*: 2011-02-15
    Sponsor Name:UZ Leuven
    Full Title: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer
    Medical condition: advanced/recurrent ovarian and endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057529 Ovarian cancer metastatic LLT
    12.1 10066697 Ovarian cancer recurrent LLT
    12.1 10057529 Ovarian cancer metastatic PT
    12.1 10066697 Ovarian cancer recurrent PT
    12.1 10014734 Endometrial cancer metastatic LLT
    12.1 10014736 Endometrial cancer recurrent LLT
    12.1 10014734 Endometrial cancer metastatic PT
    12.1 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003856-19 Sponsor Protocol Number: CVB2018-2 Start Date*: 2019-01-09
    Sponsor Name:Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK
    Full Title: A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients
    Medical condition: The trial will include participants with Xerostomia ( International Classification of Diseases-10: DQ 838A)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10048223 Xerostomia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005327-33 Sponsor Protocol Number: CFTSp060 Start Date*: 2013-06-28
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer
    Medical condition: Advanced Oesophago-gastric Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000589-31 Sponsor Protocol Number: NEMESIS Start Date*: 2018-02-02
    Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA
    Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003510-13 Sponsor Protocol Number: IRST174.08 Start Date*: 2013-05-07
    Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/A...
    Medical condition: pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004368-21 Sponsor Protocol Number: ISG-ACCesS Start Date*: 2020-09-15
    Sponsor Name:ITALIAN SARCOMA GROUP
    Full Title: Phase II study on TSR-042 in advanced clear cells sarcoma
    Medical condition: Advanced clear cells sarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073140 Clear cell sarcoma of soft tissue PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002155-17 Sponsor Protocol Number: LAP105594 Start Date*: 2008-04-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...
    Medical condition: Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004310-33 Sponsor Protocol Number: CAR4SAR Start Date*: 2022-02-21
    Sponsor Name:Dr. Antonio Pérez Martínez
    Full Title: A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma
    Medical condition: Advanced Sarcoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 19:56:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA